Life SciencesLiability
Request a review

TL;DR

Compounding pharmacy insurance sizing depends on 503A vs 503B scope, sterile vs non-sterile workflow, state license count, and ownership structure. The single highest-risk renewal verification in 2026 is whether the endorsement schedule silently added a non-FDA-approved drug exclusion - if your GLP-1 revenue line is uninsured, you should know before signing the renewal.

Compounding Pharmacies · Texas

The state board inspection is scheduled for next month. Your renewal closes the week before.

Texas compounding pharmacies operate at the intersection of state board enforcement, USP 797/800 compliance, PBM network credentialing, and increasingly aggressive carrier endorsement schedules - including GLP-1 exclusions added without prominent disclosure at renewal.

We help 503A sterile and non-sterile compounders rebuild programs around druggist professional liability with adequate scope, products coverage that does not silently exclude their lines, and property coverage that responds to sterile-suite and hazardous-drug exposures.

Get my coverage reviewCall (949) 441-9365

Choosing a broker

What to look for in an insurance broker for a compounding pharmacy.

Most compounding pharmacies are placed by a generalist agency on a retail pharmacy package. That works until a renewal adds an exclusion nobody read, or a PBM, hospital, or state board asks for something the package was never built to show. A broker who works with compounders should be able to do five things, and you can test each one in a single conversation.

  1. Read the endorsement schedule, not just the declarations page. Ask where a GLP-1, peptide, or non-FDA-approved drug exclusion would appear in your current policy and whether one is there now. Peptide exclusions can sit in the same schedule as GLP-1 language, and some are keyed to substances FDA has placed in Category 2 of its bulk drug substance lists for 503A compounding.
  2. Place druggist professional liability at the entity level. A pharmacist's individual policy follows the pharmacist. The pharmacy needs its own druggist professional liability (pharmacy E&O) covering the business, its technicians, and the compounding operation, with employed pharmacists confirmed as insureds.
  3. Know where 503A ends and 503B begins. A 503A is underwritten mainly on druggist professional liability for patient-specific prescriptions. A 503B is underwritten as a drug manufacturer, with products liability, recall, and cGMP property sized to hospital purchase contracts. A good broker can explain what changes if you add office-use compounding or register a 503B, and why a shared owner usually needs separate named insureds. The 503A vs 503B comparison covers the differences line by line.
  4. Match coverage to sterile and hazardous-drug work. Sterile compounding under USP 797 and hazardous-drug handling under USP 800 change the professional, products, and property exposures. The policy wording should name your workflow, not rely on default retail pharmacy language.
  5. Keep the paperwork your counterparties check current. PBM credentialing, hospital and clinic agreements, and state board renewals all look at certificates, additional insured wording, and notice of cancellation. A lapse here can cost network status before anyone notices.

A coverage review is a quick way to test any broker, including your current one. We read your declarations and endorsement schedule against your actual compounding scope and show you where the program responds and where it does not.

Problem 01 · USP 797 compliance

Inspection-readiness drives underwriting.

Carriers underwriting sterile compounding require current USP 797 documentation as a condition of binding. The 2023 USP 797 revision tightened beyond-use dating, environmental monitoring, and competency documentation requirements; pharmacies that updated SOPs to comply have a smoother renewal experience than those that did not.

State board of pharmacy inspections also feed into underwriting. Form 483 observations, warning letters, and recent enforcement actions all factor into renewal pricing and availability.

Problem 02 · GLP-1 exclusions

The endorsement schedule changed silently.

Several specialty pharmacy carriers added exclusions for compounded versions of FDA-approved branded drugs (semaglutide, tirzepatide) starting in 2025-2026, often without prominent disclosure at renewal. A pharmacy compounding GLP-1s under a policy with this exclusion has uninsured products liability for that revenue line.

See the dedicated GLP-1 page for the full landscape.

Problem 03 · PBM network status

A lapsed COI silently terminates the network.

PBM network agreements (Express Scripts, CVS Caremark, OptumRx) require druggist professional liability and general liability minimums plus current COI on file. A 30-day notice of cancellation lapse can trigger silent network removal - dispensing continues but claims start getting denied, with the pharmacy often discovering the lapse only after weeks of accumulated denied revenue.

Reinstatement after administrative lapse is sometimes possible. Reinstatement after a claims-driven termination is much harder. Coverage discipline at renewal is the cheapest defense.

Problem 01 · Endorsement schedule audit

Renewal endorsements quietly add exclusions you might not see until first claim.

Specialty pharmacy carriers added non-FDA-approved drug exclusions to renewal endorsement schedules across 2025 and 2026 - sometimes mid-policy, sometimes at renewal without prominent disclosure. The most common silent additions: GLP-1 exclusions, non-FDA-approved drug exclusions, weight-loss drug exclusions.

The verification is mechanical but tedious. Read every renewal endorsement, search for the exclusion keywords, document the result. We do this for clients as a standard quarterly check; operators handling it in-house should set a calendar reminder before each renewal.

Problem 02 · Druggist professional liability scope

Druggist PL scope determines whether your specific compounding errors are covered.

Druggist professional liability covers dispensing errors, compounding errors, BUD miscalculation, mislabeling, and counseling failures. Standard policies vary materially on whether sterile compounding errors, hazardous-drug handling violations, or 503B-adjacent activities fall within scope.

The fix is verifying the policy explicitly addresses your workflow scope rather than relying on default druggist PL language. Specialty compounders with high-risk product lines need $3M+ per incident as a floor.

Problem 03 · USP 797/800 property exposure

Sterile-suite and hazardous-drug exposures require specific property coverage.

USP 797 sterile compounding suites and USP 800 hazardous-drug handling areas create property exposures that standard pharmacy property policies do not address: validation losses after a covered event, sterility re-validation costs, environmental monitoring failures, and HEPA filtration system claims.

Property programs should include explicit validation loss extension and BUD-extension business interruption coverage. Operators discovering this gap at first claim are usually 90 days into a stop-compounding situation.

Problem 04 · State board defense

State board enforcement defense is the highest-frequency claim category.

State board of pharmacy enforcement - inspections, deficiency citations, license suspensions - is the most frequent claim category for compounding pharmacies. Most generalist programs include limited regulatory defense; specialty programs include dedicated state board defense scope.

The dollar amounts per proceeding are modest individually, but the cumulative drain and the license-at-risk severity make dedicated coverage load-bearing. Operators in active enforcement environments (Texas, California, Florida) typically place dedicated state board defense.

Carrier access

We place compounding programs through specialty pharmacy carriers with current GLP-1 and 503A/503B appetite.

Generalist pharmacy carriers will write a 503A compounder and silently add GLP-1 exclusions at renewal. The placement looks fine on the COI. The GLP-1 revenue line is uninsured.

Our placements run through carriers with dedicated compounding pharmacy underwriting and active appetite for GLP-1 and high-risk product lines. We know which markets still write semaglutide and tirzepatide compounders vs which exited the segment in 2025-2026.

Programs anchored in Texas with broader placement across the major US life-sciences clusters - including the New Jersey pharma corridor and the North Carolina (RTP) cluster.

Pricing

Wondering what this typically costs?

Premium ranges for 503A sterile and non-sterile compounders, the factors that drive cost, and sample programs by workflow and state.

See pricing guide →

Frequently asked

Common questions from 503A compounding pharmacy operators

How do I find an insurance broker for a compounding pharmacy?

Look for a broker who places compounding pharmacies specifically, not a retail pharmacy package. In one conversation, ask them to (1) show you where a GLP-1, peptide, or non-FDA-approved drug exclusion would appear in your current endorsement schedule and whether one is there, (2) confirm the pharmacy itself carries druggist professional liability (pharmacy E&O) at the entity level, not only the pharmacists, (3) explain how the program changes between 503A and 503B work, (4) match the wording to your sterile (USP 797) and hazardous-drug (USP 800) workflow, and (5) keep PBM, hospital, and state board certificates current. A coverage review of your existing policies is a fast way to test any broker, including your current one.

Does a compounding pharmacy need its own E&O if the pharmacists carry individual policies?

Yes. An individual pharmacist policy follows the pharmacist and protects that person. Claims over a compounding or dispensing error are usually brought against the pharmacy as well, and the business, its technicians, and its compounding operation need entity-level druggist professional liability. Confirm employed pharmacists are named as insureds on the entity policy so the two do not leave a gap between them.

What insurance does a compounding pharmacy need?

Druggist professional liability, products liability, general liability, property (with sterile-suite or hazardous-drug peril if applicable), cyber for HIPAA exposure, and crime/fidelity. Sterile compounders need higher products limits.

How does USP 797 compliance affect my premium?

Carriers underwriting sterile compounding require current USP 797 documentation as a condition. Clean inspection history can earn credit; lapses trigger non-renewal or restrictive endorsements.

Does my insurance cover GLP-1 compounding?

Maybe not - many specialty pharmacy carriers added GLP-1 exclusions in 2025-2026. Read the endorsement schedule carefully. If you compound GLP-1s, the exclusion is often the most important line in the policy.

What is the difference between 503A and 503B insurance needs?

503A patient-specific compounding uses a pharmacy-classed program. 503B outsourcing-facility status requires manufacturer-classed coverage with cGMP property, higher products limits, and FDA-specific recall language.

How long does compounding pharmacy insurance underwriting take?

Specialty markets typically need 2-4 weeks for sterile/503B accounts. Underwriting requires USP 797 documentation, current state board inspection history, and 5 years of loss runs. Plan ahead of renewal.

Do I need separate cyber coverage?

Yes. Pharmacies hold significant PHI under HIPAA, and Texas HB300 adds state-level requirements. A standalone cyber policy with HIPAA notification expense coverage is standard.

Next steps

Keep going.

Authoritative references

Primary regulatory sources for compounding pharmacy insurance

Why operators choose this practice

  • Life sciences only

    Every placement passes through specialty life-sciences underwriters - not a general manufacturer or healthcare desk.

  • All 50 US states

    Programs placed nationally with deep practice content for the 16 states anchoring the major US life-sciences clusters.

  • End-of-day SLA

    Coverage review requests come back the same business day. MSA reads are typically half an hour or less.

  • Decoder + glossary

    Free MSA Decoder, 49-clause glossary, 60+ Q&A library. Designed for CFOs, GCs, and Quality leaders.

Related deep-dives

Go deeper on the specific clauses and decisions that show up most.

503B outsourcing facilities →GLP-1 compounding →Browse all clauses →MSA Decoder tool →Florida pharmacy regulatory →Florida compounding pharmacy programs →New York state pharmacy code →

Two ways to start

Wherever you are, there is a next step.

Explore on your own

Reviewing a contract or sizing a first program?

Run your sponsor MSA, GPO supplier agreement, or hospital purchase contract through the free tools. No login, no contact, results in about fifteen minutes. Built for founders and earlier-stage operators who want to understand the requirement first.

Run the MSA DecoderAll free tools →

Talk to a specialist

Scaled operation, a live contract, or a complex program?

Multi-entity structures, high-limit towers, GPO and hospital contract portfolios, transactional and exit diligence. When the program is load-bearing, a specialist reads it clause by clause and rebuilds it to pass. End-of-business-day response.

Request a program reviewHow the review works →

Free coverage review

A specialist will reach out by end of business day.

Programs placed through A-rated specialty markets. A half-hour clause-by-clause read is the standard.

Request the review

A specialist will reach out by end of business day.

Programs placed through A-rated specialty markets. Your specialist handles unlimited certificates of insurance, annual coverage reviews, and claims advocacy.